ada glp-1 2026: Earlier and SGLT-2 Use Recommended From Diabetes Diagnosis, Expert Says ADA Updates Diabetes Treatment Guidelines

#ASCO #PublicHealth #WomenInMedicine #DiabetesCare #CancerResearch To view or add a comment, sign in More Relevant Posts Encouraging news for people living with relapsing multiple sclerosis (RMS) Last week, Novartis shared new long-term data further supporting the use of Kesimpta (ofatumumab) in treating RMS

Seek medical advice promptly if you experience : Severe or persistent vomiting : This may lead to dehydration and affect blood glucose control, and could indicate gastroparesis (severe delayed gastric emptying) Severe abdominal pain : Particularly if constant, persistent, or radiating to the back, as GLP-1 receptor agonists carry a small risk of pancreatitis Right upper abdominal pain, fever or jaundice : These may indicate gallbladder problems, which can occur with GLP-1 receptor agonists Signs of dehydration : Including dark urine, dizziness, reduced urination, or extreme thirst Inability to tolerate food or fluids : This affects both nutrition and diabetes management Blood in vomit or stools : This requires immediate medical assessment Symptoms of hypoglycaemia : Particularly if taking Victoza alongside sulfonylureas or insulin For urgent concerns, contact NHS 111 or attend your local A&E department if symptoms are severe

This isnt about getting skinny

Long-term safety data beyond two years is limited

Dehydration Many patients also drink less water without realizing it

The product is intended for adults and should be used as directed